Clinical Trial

A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of single and multiple dose regimens of SYNT-101 in healthy and overweight adults.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-14; most recent amendment 2026-04-28.
Status change: Not Yet Recruiting → Recruiting 2026-01-13
Trial Details
NCT Number NCT07307274
Lead Sponsor Syntis Bio
Conditions Healthy, Overweight and Obese Adults
Enrollment 64 participants
Start Date 2026-01-13
Primary Completion 2026-10 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-29